Loading the session
Loading the session
Loading instrument
$131.39
+3.97%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 02:30 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +25.0% (SPY −1.6%, XLV +13.5%). 3 months: +7.6% (SPY −0.4%, XLV +15.5%). 1 year: −26.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IRTC, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $134.00 was 16.3% above its 50-day average ($115.23) and 10.0% above its 200-day average ($121.79). It has closed above the 200-day for 7 sessions, since 27 Oct 2026. The 50-day average crossed below the 200-day on 27 Feb 2026, 173 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
3.1M shares were sold short at the 15 Oct 2026 settlement, 9.6% of the 32.2M shares outstanding; covering them would take 6.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
4 Nov 2026 volume of 1.2M shares was 2.3× the average of the 30 sessions before it (513.7K), as the price rose 6.0%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
The 14-session relative strength index closed at 74.1 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
October 22, 2024
+21.72%July 8, 2022
+23.16%January 10, 2022
+27.55%